Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM) Reardon, D., Kaley, T., Dietrich, J., Clarke, J. L., Dunn, G. P., Lim, M., Cloughesy, T., Gan, H. K., Park, A., Schwarzenberger, P., Ricciardi, T., Macri, M., Ryan, A., Venhaus, R. OXFORD UNIV PRESS INC. 2017: 28
View details for Web of Science ID 000415152500109